Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Issa, Ghayas C.
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca S.
Cortes, Jorge E.
Short, Nicholas James
Sasaki, Koji
Schroeder, Heather M.
Kadia, Tapan M.
Verstovsek, Srdan
Daver, Naval Guastad
Jain, Nitin
Konopleva, Marina
O'Brien, Susan Mary
Jabbour, Elias
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：4
相关论文
共 50 条
  • [11] UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Short, N.
    Kantarjian, H.
    Ravandi, F.
    Daver, N.
    Pemmaraju, N.
    Thomas, D.
    Yilmaz, M.
    Kadia, T.
    Sasaki, K.
    Garris, R.
    Garcia-Manero, G.
    DiNardo, C.
    Konopleva, M.
    Estrov, Z.
    Jain, N.
    Wierda, W.
    Jeanis, V.
    Cortes, J.
    O'Brien, S.
    Jabbour, E.
    HAEMATOLOGICA, 2017, 102 : 198 - 198
  • [12] Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Richard-Carpentier, Guillaume
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    Patel, Keyur P.
    Roberts, Kathryn G.
    Gu, Zhaohui
    Ravandi, Farhad
    Jain, Nitin
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Schroeder, Heather M.
    Kwari, Monica
    Garris, Rebecca
    Khouri, Rita
    Jones, Mike
    Loiselle, Christopher
    Cortes, Jorge E.
    Sasaki, Koji
    Issa, Ghayas C.
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Verstovsek, Srdan
    Daver, Naval G.
    Mullighan, Charles G.
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [13] Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Short, Nicholas James
    Issa, Ghayas C.
    Garris, Rebecca S.
    Jeanis, Vicky
    Moore, H. Gal
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Gachimova, Evguenia
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [14] Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Sasaki, Koji
    Jabbour, Elias J.
    Ravandi, Farhad
    Daver, Naval G.
    Pemmaraju, Naveen
    Thomas, Deborah A.
    Khouri, Rita B.
    Yilmaz, Musa
    Kadia, Tapan M.
    Short, Nicholas J.
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Wierda, William G.
    Jeanis, Twilla Victoria
    Cortes, Jorge E.
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    BLOOD, 2016, 128 (22)
  • [15] Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Updated results of a phase II study.
    Short, Nicholas James
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Daver, Naval Guastad
    Pemmaraju, Naveen
    Thomas, Deborah A.
    Yilmaz, Musa
    Kadia, Tapan M.
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    Dinardo, Courtney Denton
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Wierda, William G.
    Jeanis, Vicky
    Cortes, Jorge E.
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [17] Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study
    Sasaki, Koji
    O'Brien, Susan
    Ravandi, Farhad
    Thomas, Deborah A.
    Moore, Haim G.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Yilmaz, Musa
    Kadia, Tapan
    Garris, Rebecca
    Garcia-Manero, Guillermo
    Jeanis, Twilla Victoria
    Chahoud, Jad
    Borthakur, Gautam
    Wierda, William
    Ferrajoli, Alessandra
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [18] A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Richard-Carpentier, Guillaume
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Schroeder, Heather M.
    Khouri, Maria
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    Jain, Nitin
    Konopleva, Marina Y.
    Takahashi, Koichi
    Sasaki, Koji
    Garris, Rebecca E.
    Jabbour, Elias J.
    BLOOD, 2018, 132
  • [19] Addition of rituximab to HYPER-CVAD in the treatment of CD20-positive adult acute lymphocytic leukemia (ALL)
    Cumpston, A
    Weisenborn, R
    Ericson, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 88 - 89
  • [20] Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
    Sasaki, Koji
    Kantarjian, Hagop M.
    Morita, Kiyomi
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Wang, Sa
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Champlin, Richard E.
    Khouri, Issa F.
    Kebriaei, Partow
    Schroeder, Heather M.
    Khouri, Maria
    Garris, Rebecca
    Takahashi, Koichi
    O'Brien, Susan M.
    Jabbour, Elias J.
    CANCER, 2021, 127 (18) : 3381 - 3389
12345